Man Group’s Relmada Therapeutics RLMD Stock Holding History

Man Group’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-72,318	Closed	-$336K	–	2234
2024 Q1	$336K	Buy	+72,318	New	+$348K	﹤0.01%	1909

Other funds holding RLMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Man Group's RLMD Position: Q2 2024 in Review

Man Group sold out of Relmada Therapeutics (RLMD) in Q2 2024, closing a stake of 72,318 shares — an estimated $336K sold.

Man Group first reported a position in RLMD in Q1 2024 and held it in 1 quarter. The position peaked at $336K in Q1 2024. 79 funds tracked by Wall St. Rank hold RLMD as of Q2 2024.

Man Group reported no remaining Relmada Therapeutics position as of Q2 2024 after selling out during the quarter.
Man Group sold 72,318 Relmada Therapeutics shares in Q2 2024, an estimated $336K.
Man Group first reported a position in Relmada Therapeutics in Q1 2024 and held it in 1 quarter.
Man Group's Relmada Therapeutics position peaked at $336K in Q1 2024.
79 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2024.

Based on Man Group's 13F filing for Q2 2024, filed 14 Aug 2024.